New Diabetes Tech On The Horizon: What’s Coming By Mid-2017 In The Us?
By Lynn Kennedy, Ava Runge, and Adam Brown What Abbott, Dexcom, LifeScan, Medtronic, Tandem, and others are bringing to make diabetes easier and less burdensome Want more news just like this? We’re living in the most exciting time ever in diabetes technology, and a slew of soon-to-launch products are going to subtract hassle from living with diabetes – fewer injections and fingersticks, less math, less data overload, less pain, and less worry. Equally important, most emerging technology shows excellent potential to improve glucose outcomes that matter, among them hypoglycemia, time-in-range, hyperglycemia, and A1c. Curious what’s coming? Read on for a summary of the insulin delivery and glucose monitoring devices expected to launch in the US by mid-2017 or earlier, based on the most recent company timelines (listed chronologically). This list is not fully comprehensive, but does cover the major device launches expected. A more detailed description of each device follows further below. New Insulin Delivery Devices Tandem’s t:slim X2 Insulin Pump – October-December 2016. The latest Tandem pump will add a new Bluetooth radio and enable software updates to add future Dexcom G5 connectivity and automated insulin delivery algorithms. Medtronic MiniMed Pro Infusion Set with BD FlowSmart technology – around late 2016. The long-awaited infusion set has several key improvements, most notably a new catheter that allows insulin to flow out of two holes (less occlusions). LifeScan’s OneTouch Via – early 2017. The bolus-only, super slim wearable device holds 200 units of insulin and can be worn for three days. Squeezing two buttons (including through clothes) – will discreetly deliver a two-unit bolus. Medtronic’s MiniMed 670G/Enlite 3 Hybrid Closed Loop – by Ap Continue reading >>
Medtrum Introduce A New Tubeless Insulin Pump And Cgm System
Please Note the Medtrum PUmp and CGM system is now available, please find the latest information in our Article on the Medtrum A6 Touchcare System as this particular article is now outdated. Exciting news in the Type 1 Community as a brand new Tubeless Insulin Pump and a new CGM system is set to be launched in the UK by Medtrum. Medtrum are a Chinese company though they have a UK office in Watford. Here is what we know about both systems, so far. MEDTRUM S6 EASYSENSE CGM The first product they are set to launch is their S6 Easysense Disposable CGM System. A company spokesperson informed me this is set to be launched in September 2016. The S6 CGM is set to rival the Dexcom G5 and quite possibly the Freestyle Libre, flash glucose monitoring system. I’m sure many families will be attracted to the product as there are no set up fees. Unlike the Dexcom system where you need to purchase a receiver and the rest of the kit up front. The company describe it as a “pay as you go, monthly format”. As you can see from the image above the S6 sensor and transmitter look very similar to the Dexcom system. This is also a mobile system, so no receiver is required, unlike the Dexcom, where despite the mobile app being widely used, users are still forced to also purchase a costly receiver, which many families find they do not use. Data from the sensor will be viewable on a mobile phone, though there is no information at this stage if that will be for both IOS devices and Android. Just like Dexcom G5 the data can be shared with love ones enabling remote monitoring of your child’s levels. Sensor life is 7 days, though it remains to be seen if the life can be extended on the sensor like you can with other CGM systems. Also highly attractive for users, is the fact that the system offer Continue reading >>
- Practical Approach to Using Trend Arrows on the Dexcom G5 CGM System for the Management of Adults With Diabetes | Journal of the Endocrine Society | Oxford Academic
- Accessing Insulin Pumps and CGM’s
- After 20 Years of Watching Diabetes Tech, Kliff Eyes Smart Insulin Pens, CGM for Patients With Type 2 Diabetes
Insulet Reports Third Quarter 2015 Financial Results
BILLERICA, Mass., Nov. 5, 2015 /PRNewswire/ -- Insulet Corporation (NASDAQ: PODD), the leader in tubeless insulin pump technology with its OmniPod® Insulin Management System, today announced financial results for the three months ended September 30, 2015. Third Quarter Revenue Results: Total revenue of $87.3 million exceeds the Company's expectations of $82 to $85 million. U.S. OmniPod revenue of $50.0 million. International OmniPod revenue of $13.5 million. Drug Delivery revenue of $7.1 million. Neighborhood Diabetes revenue of $16.7 million. "We are excited about our results, with year-over-year revenue growth across all four of our product lines and top-line results again ahead of expectations," said Patrick Sullivan, President and Chief Executive Officer. "Our team has made great progress in our commercial efforts focused on increasing patient and clinician demand for OmniPod and delivering an outstanding customer experience. We are also excited by the results in our drug delivery business, where we continue to create a solid foundation to support long-term revenue growth and significant value creation." Third Quarter 2015 Financial Results: Third quarter 2015 revenue increased 16% to $87.3 million compared with $75.0 million in the third quarter of 2014. Operating loss for the third quarter of 2015 was $15.7 million, compared with an operating loss of $2.9 million for the third quarter of 2014. This result was primarily driven by: 1) non-recurring charges of $7.7 million associated with certain product which ultimately did not meet the Company's quality expectations; and 2) increased investment in commercial and development initiatives, in-line with the Company's previously announced expectations. Net loss for the third quarter of 2015 was $18.9 million, or $0.33 Continue reading >>
Global Insulin Pumps (external) Industry
NEW YORK, Nov. 17, 2017 /PRNewswire/ -- This report analyzes the worldwide markets for Insulin Pumps (External) in US$ Thousand. Read the full report: The report provides separate comprehensive analytics for the US, Canada, Europe, Asia-Pacific, Latin America, and Rest of World. Annual estimates and forecasts are provided for the period 2015 through 2022. Also, a six-year historic analysis is provided for these markets. Market data and analytics are derived from primary and secondary research. Company profiles are primarily based on public domain information including company URLs. The report profiles 15 companies including many key and niche players such as: - Debiotech S.A. - F. Hoffmann-La Roche, Ltd. - Insulet Corp. - Medtronic Plc. - Sooil Development Co. Ltd. - Tandem Diabetes Care Inc. Read the full report: INSULIN PUMPS (EXTERNAL) MCP-1511 A GLOBAL STRATEGIC BUSINESS REPORT CONTENTS I. INTRODUCTION, METHODOLOGY & PRODUCT DEFINITIONS Study Reliability and Reporting Limitations Disclaimers Data Interpretation & Reporting Level Quantitative Techniques & Analytics Product Definitions and Scope of Study II. EXECUTIVE SUMMARY 1. INDUSTRY OVERVIEW Insulin Pumps: A Prelude Key Benefits Offered Infuse Sustained Growth Opportunities Developed Regions Underpin Sales Growth The United States - The Largest Market Europe - A Market with Vast Potential Lower Current Penetration Leaves Significant Room for Growth Table 1: Insulin Pumps Market by Region (2016): Percentage Breakdown of Number of Users for Established Markets and Rest of World (includes corresponding Graph/Chart) Table 2: Insulin Pump Penetration Rate (as a % of Total Diabetics) in Type 1 Diabetic Patients by Country (2016) (includes corresponding Graph/Chart) Rising Incidence of Diabetes - A Major Market Driving Continue reading >>
Tubed Vs. Tubeless: Insulin Pump Comparison
It’s been more than ten years since Caleb began pumping. That’s more than 1,500 pods, roughly estimating. Caleb was four when we decided to use Omnipod. He didn’t have much say in the matter. Over the years, we’ve talked about other pumps. I thought he might be intrigued by the t:slim because of its slick touch screen. Not so. “Does it have a tube? Yes? No, thanks.” Simple as that. Traveling on his own and wanting the benefit of closed loop technology that was only available with a tubed pump changed his perspective. Now that we have first-hand experience with a tubed pump, I can provide a user comparison of it to a tubeless one. The process of changing a site and reservoir is much more involved than filling a pod and inserting it. There are so many more steps. It’s not difficult – Caleb took over immediately and I don’t even remember what to do – but it’s definitely simpler with Omnipod. Being tethered takes some getting used to. Caleb adjusted quickly. Figuring out what to do with the tube with certain clothing, in particular a dress shirt and khakis, was a little perplexing. I sympathize with the ladies wearing dresses. This is probably no longer relevant with newer tubed pumps, but the screens and menus of the older model Medtronic pumps – just ugh. I now appreciate all the comments about failed pods. This was never a problem for us. Yes, we had the occasional pod error, but we didn’t know any differently. It’s what we experienced from the very beginning and we learned to be prepared for it – always carrying extra pods, insulin and alcohol. No biggie. After using a tubed pump, which almost never errors (we did have a pump go kaput – not fun), I understand how someone switching to Omnipod would find these errors completely unacceptable Continue reading >>
- Relative effectiveness of insulin pump treatment over multiple daily injections and structured education during flexible intensive insulin treatment for type 1 diabetes: cluster randomised trial (REPOSE)
- Insulin Pump Therapy for Kids
- Comparative Effectiveness and Costs of Insulin Pump Therapy for Diabetes
Pump Maker Deals With Quality Control Fallout
Insulet touts improved OmniPod manufacturing standards just as FDA details summer recall notice of the pumps. Insulet, known for the OmniPod tubeless insulin pump, recently announced that its manufacturing plant was functioning quite nicely again after a rocky period of quality control issues. This announcement, of course, came just before the FDA released details of a July recall notice that affected over 400,000 OmniPods. The recall was issued because regulators in March found that the Billerica, Massachusetts-based pump manufacturing facility had “inadequate standards compliance” issues, according to a Fierce Medical Devices article report. There were 90 reported complications with the OmniPod device, 13 of which required medical intervention, the FDA recall notice explained. This included an instance of the device’s cannula retracting or not fully deploying, which means no insulin delivery. The OmniPod recall notice, which Insulet told customers was voluntary, was only for the OmniPod itself and not for the accompanying Personal Diabetes Manager device that wirelessly communicates with the insulin delivery pod. In response to concerns of quality control, Insulet brought on Michael Spears, giving him the title of vice-president of quality, regulatory and clinical affairs. Spears held a similar position with Covidien, another Massachusetts-located medical device supplier. Insulet has also implemented improved quality control procedures and have received the FDA’s blessing to continue production. It’s often said that timing is everything in business. It appears Insulet was extremely unlucky in the timing of its public relations moves. Thanks for reading this Insulin Nation article. Want more Type 1 news? Subscribe here. Have Type 2 diabetes or know someone wh Continue reading >>
Tubeless Insulin Pump Market Growth
Improved product functionality is a determinant that may incite investors to pour in their money in tubeless insulin pump industry. Insulet’s latest addition of smart features to its product is an instance of the aforementioned statement. Elaborating further, Insulet Corporation, a renowned player across tubeless insulin pump industry, has recently added additional features such as touchscreen and Bluetooth to its OmniPod Dash system. Citing yet another example, in 2016, Medtrum Technologies Incorporation, a key participant in tubeless insulin pump market, had launched a tubeless insulin punch fitted with CGM system. Even Roche Holdings AG, a healthcare firm based in Switzerland, in 2015, introduced the Accu-Chek Connect – a bolus calculator, in its tubeless insulin pump, that has apparently helped numerous users to calculate the proportion of insulin doses to be consumed. Germany Tubeless Insulin Pump Market, By Component, 2013 – 2024 (USD Million) Critical agreements between prominent industry giants have ushered in new developments across tubeless insulin pump industry. Quoting an example, in 2016, Insulet Corporation and Eli Lilly & Company, a U.S. based pharmaceutical giant, had signed a pact to build a new type of OmniPod tubeless insulin delivery system to deliver Lilly’s highly concentrated U200 and U500 insulin formulations. It is undeniable therefore, that collaborations witnessed across the pharmaceutical and healthcare industry can have a major impact on the overall business. Tubeless insulin pumps find a remarkably high demand over their tubed counterparts across the United States. This, as the experts say, is a key determinant that will facilitate the development of North America tubeless insulin pump market. In 2016 alone, U.S. tubeless insulin pu Continue reading >>
- NEWSFLASH: Animas Exiting Insulin Pump Market
- Relative effectiveness of insulin pump treatment over multiple daily injections and structured education during flexible intensive insulin treatment for type 1 diabetes: cluster randomised trial (REPOSE)
- Growth in diabetes products lags, but Medtronic earnings solid
Insulin Pump Reviews From Diabetesmine
For anyone taking long-acting and short-acting (pre-meal) insulin, an insulin pump offers freedom from all of the hassle of injections. If you decide to eat a little more, or do some unexpected exercise, you can just push a button to administer more or less insulin. And the pump’s continuous background drip of insulin mimics the action of a healthy pancreas, so your blood sugar levels can remain much steadier. Note that an insulin pump is NOT an artificial pancreas or a fully automated cure for diabetes. The person wearing it still has to decide how much insulin they need and when they need it. This makes the user the most important part of the pump. But no worries – modern pumps are very intuitive and easy to use. And there’s no age limit on using a pump; they are used by infants, all the way up to senior citizens. Here are our reviews of some of the existing insulin pumps available here in the United States (in alphabetical order): Animas OneTouch Ping Insulin Pump (combo with glucose meter) A combination of the Animas 2020 insulin pump and OneTouch glucose (fingerstick) meter that talk to each other wirelessly. This means you can actually control the pump right from the glucose meter — setting basal rates and bolus insulin doses — without ever having to "pull the pump off your hip." Animas Vibe Insulin Pump (combo with continuous glucose monitor) New! Just approved by the FDA in November 2014 and available to customers in early 2015, this is a combination of the Animas insulin pump and the popular Dexcom G4 continuous glucose monitoring (CGM) system. The CGM data is displayed directly on the insulin pump’s screen, so there's no need to carry a separate receiver. Asante Snap Insulin Pump (no longer available) This was a unique full-featured insulin pump th Continue reading >>
- Relative effectiveness of insulin pump treatment over multiple daily injections and structured education during flexible intensive insulin treatment for type 1 diabetes: cluster randomised trial (REPOSE)
- Insulin Pump Therapy for Kids
- Comparative Effectiveness and Costs of Insulin Pump Therapy for Diabetes
Insulin Pump Choices... Are You Ready For Tubeless?
Johanna and Nick, both age thirteen, were making a new pump choice last year. They were both interested in Insulet's OmniPod pump system, and since OmniPod pods were recently reduced to a smaller size looking like a tiny flattened computer mouse, it was even more appealing to them. Their other pumps had served them well. However a situation last year prompted Johanna to want a less conspicuous pump. While working as a counselor with young children she was repeatedly asked about the tube running to her pouch containing the pump, "What is that thing?" and "What does that tube do?" Johanna is not shy about her diabetes but she realized she didn't want it to be the first impression about her. The timing was right for a change. For the most part the newly designed pods have been fantastic. Notwithstanding some failed pods here and there, the transition to the OmniPod has been in the kids' words, "life changing": No more pouch worn around the waist, fear of the tube being caught on anything. Now they change their infusion sets on their own. It's been about six months since they've gone tubeless. Some of the changes were big such as they wear their pods during sport and swimming instead of having to remove their pumps and miss important basal insulin during the removal. Other changes are smaller. One has to suspend the Omnipod's PDM to make any changes and resume afterwards. Here are some takeaways from our experience. The PDM which looks like a chunky smart phone is the center of the system. This is where the pump settings are programmed and blood sugar tested. It's the only way to program an insulin bonus. The Pods need to be changed every three days. If not changed within the allotted time, and after much warning the pod will shut down so you are forced to change it. The PD Continue reading >>
Freestyle Libre – A Nurse’s Review
My 15 year old daughter and I both started on the Medtronic 670G system in July. With 2 1/2 months of use under our belts, we have had common, yet unique, experiences with the Medtronic 670G tech. As many people report, some magic happens between weeks 3 and 5. There was a turning point in which we both became happier with the results and user interface/ demands. [Our initial experience, one week in, is documented in this piece: A Nurse’s Review: Medtronic 670G Insulin Pump.] Chew on this: I don’t buy juice anymore. This is huge, especially in a household that has two very active people under one roof – that both have T1D. I had the habit, on occasion, of pouring my daughter 3 glasses of juice overnight after a big basketball practice or some crazy family adventure in the mountains. I can thankfully report that this behavior is a thing of the past. Like it or not, midnight picnics are common for those of us living with type 1 diabetes. Our dentists may agree that the 670G may be worth it’s weight in gold with the simple elimination of the sugar bath on our teeth all hours of the day and night. Hands down, the best feature of this pump/ sensor combo is the near elimination of hypoglycemia (low blood sugar) – particularly overnight when we are at our most vulnerable. Over the past few months I have put this thing to the test. I trained for and completed a 102 mile bike ride for JDRF Ride to Cure in Loveland, Colorado. I’ve spent a lot of time in the saddle with this sensor and pump over some strenuous miles at higher elevations. My overall impression is quite positive at this point – I have no desire to go back to my previous pump or a pump/continuous glucose monitor (CGM) that don’t speak to one another. Do I have high blood sugars? Yes. Do I get frustrat Continue reading >>
Omnipod Is The Worlds Only Tubeless Insulin Pump
sponsored post November is Diabetes Awareness month and there are a lot of pretty compelling reasons to choose OmniPod® for your insulin needs, starting with the freedom you'll experience. Then there's the convenience and the control. OmniPod gives you or your child the freedom to do what you want, when you want; sleep in, exercise, and just live life on your own terms, because you don’t want to be tethered to your insulin schedule or a pump. The Juicebox Podcast is proud to be sponsored by Insulet, the makers of Arden's insulin pump! The best way to understand OmniPod® is to try it yourself. So get a free Demo Kit, including a sample, non-functioning Pod, by going to www.myomnipod.com/demo and see what you think. There's no obligation. Continue reading >>
- Only 2 Ingredients and You Can Say Goodbye to Diabetes Forever! No More Medications and Insulin!!!
- Relative effectiveness of insulin pump treatment over multiple daily injections and structured education during flexible intensive insulin treatment for type 1 diabetes: cluster randomised trial (REPOSE)
- The Only Way To Prevent Or Reverse Type II Diabetes
An Overview Of Insulin Pumps And Glucose Sensors For The Generalist
Go to: 1. Introduction Diabetes is rapidly becoming a major health epidemic in most regions of the world [1]. All patients with type 1 diabetes and a significant number with type 2 diabetes require the use of insulin for controlling blood glucose. In the last 20 years, technological innovation and bioengineering has transformed the diabetes therapeutic landscape. There are several varieties of insulin and many different injection regimens that can be used. However, in spite of the availability of insulin vials and pens, the acceptability for patients and the glucose readings that are obtained with the use of single or multiple-dose injection regimens is not to the desired level. Insulin delivery with pumps, also known as continuous subcutaneous insulin infusion (CSII), was introduced almost a half century ago. It utilizes short- or rapid-acting insulin types only, thus minimizing variability of administration and reducing the chances of glucose fluctuations. Pump technology has progressed to the level of precisely mimicking physiological demands. Programmable insulin administration in basal and bolus fashion is integrated and augmented with glucose biosensors to provide real-time, data-driven glycemic control and early detection of hypoglycemia. The prospect of a functional, closed-loop “artificial pancreas” with implantable or bionic capabilities is now within the realm of technological possibility in the near future. Continue reading >>
Attd. Closed-loop Diabetes Tech Update, A Crescendo: Ilet, Bigfoot, Typezero & More
This million-dollar clinical study will utilize Type Zero's inControl AP diabetes management platform (which we first told you about in June 2015) as the core analytic and control technology. Originally known as the DiAs (Diabetes Assistant system) and developed from a prototype licensed from the University of Virginia (UVA) in 2013, the startup changed the name last year to inControl. Slated to kick off in the first half of 2016 and managed by Dr. Boris Kovatchev at the Center for Diabetes Technology at UVA, the study is called International Diabetes Closed Loop Trial (IDCL). It will include multiple sites -- two in the United States and three internationally in France, Italy, and the Netherlands. It will test InControl with 240 people during a six-month at-home study, setting the stage with data for a final regulatory submission in 2017; even though the trial's is set to last 2.5 years, the first six months of data gathered will likely be used to make an FDA filing. The full system being studied uses insulin only and runs a control algorithm on an Android smartphone that communicates with a Roche or Tandem insulin pump as well as a Dexcom CGM. We're told the system is "pump agnostic" so they will test two or three other pump models in the mix as well. Study participants will "treat-to-range," meaning they will only be responsible for setting meal boluses, while the system will work to keep the patient's glucose levels within a designated range by tweaking insulin basals automatically. Overnight, it will be programmed to keep BGs between 110-120 mg/dL (nice!). This is the system that some may remember in its prototype phase as looking a bit like a stoplight. A new mobile smartphone app that communicates with the pump and CGM has replaced that original UI, with a design Continue reading >>
Insulin Pump
An insulin pump is a medical device used for the administration of insulin in the treatment of diabetes mellitus, also known as continuous subcutaneous insulin infusion therapy. The device configuration may vary depending on design. A traditional pump includes: the pump (including controls, processing module, and batteries) a disposable reservoir for insulin (inside the pump) a disposable infusion set, including a cannula for subcutaneous insertion (under the skin) and a tubing system to interface the insulin reservoir to the cannula. Other configurations are possible. For instance, more recent models may include disposable or semi-disposable designs for the pumping mechanism and may eliminate tubing from the infusion set. An insulin pump is an alternative to multiple daily injections of insulin by insulin syringes or an insulin pen and allows for intensive insulin therapy when used in conjunction with blood glucose monitoring and carb counting. Medical uses[edit] Advantages[edit] Users report better quality of life (QOL) compared to using other devices for administering insulin. The improvement in QOL is reported in type 1 and insulin-requiring type 2 diabetes subjects on pumps.[1] The use of rapid-acting insulin for basal needs offers relative freedom from a structured meal and exercise regime previously needed to control blood sugar with slow-acting insulin.[citation needed] Programmable basal rates allow for scheduled insulin deliveries of varying amounts at different times of the day. This is especially useful in controlling events such as the dawn phenomenon resulting in less low blood sugar during the night.[2] Many users feel that bolusing insulin from a pump is more convenient and discreet than injection.[2][3] Insulin pumps make it possible to deliver more pre Continue reading >>
- Relative effectiveness of insulin pump treatment over multiple daily injections and structured education during flexible intensive insulin treatment for type 1 diabetes: cluster randomised trial (REPOSE)
- Insulin Pump Therapy for Kids
- Comparative Effectiveness and Costs of Insulin Pump Therapy for Diabetes
Hybrid Closed Loop System.
NEW! The Suspend before low§ option avoids lows and rebound highs proactively by automatically stopping insulin 30 minutes before you reach your pre-selected low limits, then automatically restarts insulin when your levels recover, all without bothersome alerts. NEW! The Auto Mode‡ option automatically adjusts your basal insulin delivery every 5 minutes based on your sugar levels to keep you in target range, all day and night. Watch Video View Brochure Get Started NEW! Guardian® Sensor 3 continuous glucose monitoring sensor. Introducing the most accurate sensor from Medtronic, now with up to 7 day wear and easy insertion. It is the FIRST and ONLY continuous glucose monitoring sensor FDA approved and trusted to control insulin dosing. Exclusive CONTOUR®NEXT LINK 2.4 meter1 Get easy and accurate CGM calibration, insulin dosing and remote bolusing with our exclusive meter. “This device will mean peace of mind, in knowing a person will be in normal blood sugar range a great majority of the time,” “It’s a medical device with the potential to change the lives of more than 1 million Americans who suffer from Type 1 diabetes.” KEEP YOUR GLUCOSE IN RANGE SMARTGUARD® HCL TECHNOLOGY. Quick and easy access to your glucose and insulin information, all from the home screen. Bright color screen for easy readability - day or night. Waterproof - so you can enjoy underwater activities. Quick and easy bolus from your meter. Fewer shots than multiple daily injections. The only sensor FDA approved and trusted to control insulin dosing. Easy to insert. Know at all times where your glucose levels are trending. Click here for assistance if your insurance does not currently cover the MiniMed 670G system. * Mean Absolute Relative Difference. ** 3-4 calibrations per day required. Continue reading >>
